[ET Net News Agency, 7 January 2022] Zai Lab Limited (09688) said the China National
Medical Products Administration has accepted the new drug application (NDA) for
margetuximab, an investigational, Fc-engineered monoclonal antibody that targets human
epidermal growth factor receptor 2 (HER2).
The margetuximab NDA is for the treatment of adult patients with metastatic
HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at
least one of which was for metastatic disease, in combination with chemotherapy. (RC)